ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
Consun Pharmaceutical Group
C1PConsun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China. Address: 71, Dongpeng Avenue, Guangzhou, China
Analytics
מחיר יעד של וול סטריט
76.41 HKDיחס רווח למחיר
7.3982תשואת דיבידנד
6.94 %השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח C1P
ניתוח דיבידנדים C1P
גידול דיבידנד במשך 5 שנים
350 %צמיחה מתמשכת
1 שנהיחס תשלום ממוצע של 5 שנים
93 %היסטוריית דיבידנדים C1P
שווי מניות C1P
פיננסיים C1P
תוצאות | 2019 | דינמיקה |